With the development of genome-wide RNAi approaches, the cost and time involved in target identification, validation and other aspects of drug discovery could be significantly reduced. Ashworth and colleagues review technologies available for RNAi screens and discuss how cancer drug discovery can benefit from their application.
- Elizabeth Iorns
- Christopher J. Lord
- Alan Ashworth
